News & Updates

Study suggests dupilumab QW/Q2W dose as maintenance for atopic dermatitis

22 Jan 2020 by

A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.

Study suggests dupilumab QW/Q2W dose as maintenance for atopic dermatitis

22 Jan 2020

Brodalumab sustains long-term safety, efficacy in psoriatic patients

20 Jan 2020 by

Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Brodalumab sustains long-term safety, efficacy in psoriatic patients

20 Jan 2020

Office, workshop workers at high risk for vitamin D deficiency

20 Jan 2020 by

Office and workshop workers were at a greater risk for vitamin D deficiency compared with control room workers, according to a recent Singapore study.

Office, workshop workers at high risk for vitamin D deficiency

20 Jan 2020

News & Updates

Filter by Specialty:

Specialty:

Study suggests dupilumab QW/Q2W dose as maintenance for atopic dermatitis

Study suggests dupilumab QW/Q2W dose as maintenance for atopic dermatitis

Brodalumab sustains long-term safety, efficacy in psoriatic patients

Brodalumab sustains long-term safety, efficacy in psoriatic patients

Office, workshop workers at high risk for vitamin D deficiency

Office, workshop workers at high risk for vitamin D deficiency